Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

T-DXd Fails to Receive Recommendation From NICE for HER2-Low Breast Cancer Treatment

March 6th 2024

The UK’s NICE has announced that it will not recommend the use of trastuzumab deruxtecan for the treatment of patients with HER2-low breast cancer.

Avelumab Maintenance Proves Equally Effective in Real-World Urothelial Carcinoma Population

March 1st 2024

Frontline maintenance therapy with avelumab following platinum-based chemotherapy led to similar outcomes in routine clinical practice and the JAVELIN Bladder 100 trial in metastatic urothelial cancer.

Molecular Correlates May Be Key in Unleashing the Full Potential of Immunotherapy in NSCLC

February 29th 2024

Ashish Saxena, MD, PhD, discusses the movement of targeted and immune therapies in non–small cell lung cancer treatment.

FDA Approves Label Expansion for Oral Ibrutinib Suspension in All Current Indications

February 28th 2024

The FDA has approved a label expansion for ibrutinib with an oral suspension formulation in all current indications.

Rusfertide More Than Triples Responses Vs Placebo in Phlebotomy-Dependent Polycythemia Vera

February 27th 2024

Rusfertide displayed activity in phlebotomy-dependent polycythemia vera.

FDA Confirms Decision to Withdraw Melphalan Flufenamide Approval in Multiple Myeloma

February 23rd 2024

The FDA has determined that sufficient criteria have been met to withdraw the approval for melphalan flufenamide in patients with multiple myeloma.

FDA Accepts BLA for Datopotamab Deruxtecan in Pretreated Advanced Nonsquamous NSCLC

February 19th 2024

A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.

Roivant Sciences to Discontinue RVT-2001 Development in Myelodysplastic Syndrome

February 15th 2024

Investigation of RVT-2001 will be discontinued following an insufficient display of benefit in patients with myelodysplastic syndrome.

FDA Grants Fast Track Designation to BXCL701 for Small Cell Neuroendocrine Prostate Cancer

February 12th 2024

BXCL701 has been granted fast track designation for select patients with metastatic small cell neuroendocrine prostate cancer by the FDA.

Chest CT Imaging Patterns Contradict ACR Guidelines for Extremity Sarcoma Staging and Surveillance

February 10th 2024

R. Lor Randall, MD, FACS, explains the next steps in ensuring adherence to clinical care guidelines in extremity sarcoma.

Apalutamide Plus ADT Improves PSA-PFS in High-Risk Biochemically Relapsed Prostate Cancer

February 9th 2024

Apalutamide plus androgen deprivation therapy improved prostate-specific antigen progression-free survival in castration-sensitive prostate cancer.

Belantamab Mafodotin Plus Vd More Than Doubles PFS in Relapsed/Refractory Multiple Myeloma

February 6th 2024

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

FDA Grants Fast Track Designation to BNT325/DB-1305 for Platinum-Resistant Ovarian Cancer

February 5th 2024

FDA grants fast-track status to BNT325/DB-1305 for patients with platinum-resistant ovarian epithelial, fallopian tube, or primary peritoneal cancer.

EMA Accepts Marketing Authorization Application for Linvoseltamab in R/R Multiple Myeloma

February 2nd 2024

The EMA has accepted for review an MAA seeking the approval of linvoseltamab for use in select patients with relapsed/refractory multiple myeloma.

FDA Grants Fast Track Designation to BST02 for Liver Cancer

February 1st 2024

The FDA has granted a fast track designation to the T-cell therapy BST02 for the treatment of patients with all forms of liver cancer.

VDA-1102 Demonstrates Favorable Activity in Mycosis Fungoides

January 29th 2024

VDA-1102 led to an objective response rate of 56% in patients with mycosis fungoides, according to findings from an interim analysis of a phase 2a study.

Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups

January 27th 2024

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

NICE Recommends Talazoparib for Advanced BRCA1/2-Mutant, HER2– Breast Cancer

January 22nd 2024

NICE has recommended talazoparib for the treatment of patients with advanced or metastatic HER2-negative breast cancer with germline BRCA1/2 mutations.

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

January 20th 2024

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

FDA Grants Orphan Drug Designation to PTX-252 for AML

January 19th 2024

The FDA has granted an orphan drug designation to PTX-252 for the treatment of patients with acute myeloid leukemia.